Merit Medical Systems (MMSI) investor relations material

Conference overview

• Event featured a fireside chat with the CFO, focusing on strategic planning and business evolution.

• Discussion covered recent leadership transition and the ongoing development of a new long-range plan (LRP).

• Emphasis on the company's eight business platforms and a new reporting structure to enhance transparency.

• Board changes and new executive leadership are seen as positive for culture and accountability.

• The event highlighted the breadth of analyst coverage and engagement opportunities for investors.

Strategic initiatives and business transformation

• Foundations for Growth initiative began over five years ago to prepare for leadership succession and process improvements.

• New reporting divides business into Foundational and Therapeutic platforms, clarifying growth sources and value drivers.

• Accountability is now pushed down to platform leads, aligning internal operations with external communications.

• Strategic planning is ongoing, with a new LRP expected to be announced around the fourth quarter.

• Focus remains on revenue growth, operating margin expansion, and free cash flow as key performance metrics.

Financial performance and guidance

• Operating margin expanded by 850 basis points since December 2019, with a target of 950 basis points by end of 2026.

• Q2 organic growth was the strongest in three years, driven by recovery in OEM and successful recall management.

• Full-year revenue guidance was raised to approximately 7–7.5% growth at the midpoint.

• Seasonal trends are expected, with a typical Q3 slowdown and Q4 rebound.

• Gross margin expansion attributed to pricing discipline, product mix, and operational efficiencies.